Top Medical News
Bisoprolol does not prevent COPD flare-ups
an hour ago
The use of bisoprolol does not appear to yield reductions in the number of self-reported chronic obstructive pulmonary disease (COPD) exacerbations requiring treatment with oral corticosteroids, antibiotics, or both, as shown in the placebo-controlled Bisoprolol in COPD Study (BICS).
A spoonful of olive oil a day may keep death at bay
Jairia Dela Cruz, an hour ago
People who consume higher amounts of olive oil are less likely to die with dementia compared with those whose intake is minimal, as shown in a study.
Limit intake of ultra-processed food to prolong life: study
Stephen Padilla, 6 hours ago
Individuals who regularly eat ultra-processed foods are at greater risk of death, which is driven by causes other than cancer and cardiovascular diseases (CVD), reports a study.
Mobile app helps diabetic patients, their caregivers put their best foot forward
Audrey Abella, 8 hours ago
An NTU*-led research team developed WellFeet, a mobile application to equip diabetic patients and their caregivers with knowledge about diabetes and assist them in monitoring their daily routines.
Dietary anthocyanin may help manage uric acid levels in women
12 hours ago
Women who consume anthocyanin-rich foods in high amounts appear to have a lower prevalence of hyperuricaemia, regardless of the presence of metabolic syndrome, as reported in a study.
Gepotidacin as good as current standard treatment for urogenital gonorrhoea
Elvira Manzano, 18 hours ago
The oral investigational antibiotic gepotidacin is noninferior to the current standard treatment for uncomplicated urogenital gonorrhoea in the randomized, multicentre, phase III EAGLE-1 trial.
IBD patients undergoing colectomy at high risk of kidney complications
The rates of acute kidney injury (AKI) and kidney failure appear to rise following colectomy, especially total colectomy or colectomy with a prolonged stroma, in patients with inflammatory bowel disease (IBD), according to a nationwide Swedish cohort study.
Special Reports
Debunking the myths about DPP-4 inhibitors
01 May 2024
Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.
Product Highlight - MENQUADFI
13 Apr 2024
Meningococcal group A, C, W & Y conjugate vaccine 0.5 mL solution for injection
Product Highlight - LYPSTAPLUS
11 Apr 2024
Rosuvastatin + Ezetimibe 10/10 mg and 20/10 mg film-coated tablet
Nirmatrelvir reduces the risk of long COVID
05 Mar 2024

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.1

COVID-19, influenza, death, hospital admission, adverse outcome
07 Feb 2024
A comparative analysis has shown that COVID-19 is distinctly more severe than seasonal influenza, with significantly increased long-term risks of adverse health outcomes and burdens.1
fenofibrate, metabolic syndrome, statins, omega-3 fatty acids, MACE
05 Feb 2024
A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.1
Treating type 2 diabetes mellitus with G.R.A.C.E.
22 Jan 2024
A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.
Conference Reports
Gepotidacin as good as current standard treatment for urogenital gonorrhoea
Elvira Manzano, 24 May 2024
The oral investigational antibiotic gepotidacin is noninferior to the current standard treatment for uncomplicated urogenital gonorrhoea in the randomized, multicentre, phase III EAGLE-1 trial.
Mum’s infection during pregnancy may raise newborn’s risk of IBD
Jairia Dela Cruz, 23 May 2024
Exposure to any infection during early pregnancy or to a gastrointestinal infection during late pregnancy contributes to the increased likelihood of inflammatory bowel disease (IBD) development, especially Crohn’s disease, in the offspring, according to a study.
Children, teens with EoE respond to budesonide oral suspension
Jairia Dela Cruz, 22 May 2024
Budesonide oral suspension is well tolerated and superior to placebo at inducing remission in paediatric patients with eosinophilic esophagitis (EoE), with the high-dose formulation offering the best results, according to the results of the phase II/III PEDEOS-1 trial.
Fibre intake may prevent celiac disease in first 2 years of life
Stephen Padilla, 22 May 2024
Increased intake of dietary fibre at age 2 years and below tends to reduce the risks for celiac disease (CD) and celiac disease autoimmunity (CDA) in genetically at-risk children, suggests a study presented at the recent ESPGHAN 2024.
Dupilumab reduces exacerbations in type 2 asthma regardless of ICS dose
Elaine Soliven, 22 May 2024

Treatment with dupilumab significantly reduced the annual rate of severe exacerbations in children with uncontrolled, moderate-to-severe type 2 asthma who were on high- or medium-dose inhaled corticosteroid (ICS), according to a study presented at PAS 2024.

Immune-mediated gut problems tied to eating disorders
Jairia Dela Cruz, 21 May 2024
People with immune-mediated gastrointestinal (GI) disease, especially children, are more prone to eating disorders, as shown in a study.
Vedolizumab helps induce steroid-free remission in children with IBD
Stephen Padilla, 21 May 2024
Use of vedolizumab as maintenance treatment in children with inflammatory bowel disease (IBD) results in sustained steroid-free remission, with an acceptable safety profile, according to the results of the 54-week follow-up of the VedoKids Study presented at ESPGHAN 2024.